SVRASavara Inc.
5.590USD+0.18%Mkt Cap: 1.15B $P/E: —3d ago
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulati…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 What Insmed Stock's Premium Is Actually Buying Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials. | ||
 Here's Why You Should Add Savara Stock to Your Portfolio Now SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook. | ||